Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Clinical trial NCT01295632 · COMPLETED
Trial details
- NCT number
- NCT01295632
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-12-01
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.